CSF and plasma biomarkers for AD, such as Aβ40, Aβ42, and their ratio, and phosphorylated tau (pTau181, pTau217), can help differentiate LBD and AD or may identify co-pathology [29, 30]. The gene discussed is MAPT; the disease is Alzheimer disease.